Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil may cause heart issues in animals and humans.

This study found that a novel effervescent formulation significantly increased minoxidil sulphate accumulation in hair follicles and skin compared to a standard minoxidil solution.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

This study found that combining minoxidil and retinol additively promoted hair growth in vitro, enhancing Erk- and Akt-dependent pathways and preventing apoptosis in dermal papilla cells and keratinocytes.

This study found that minoxidil did not significantly increase hair shaft elongation in ex vivo human hair follicle culture, questioning the suitability of this method for studying its hair-growth-promoting effects.

In this study, researchers measured the solubility of Minoxidil in supercritical CO₂ under various temperature and pressure conditions and created models to estimate solubility based on different predictive approaches.

This study found that polymeric nanoparticles retained more minoxidil and facilitated superior drug permeation compared to lipid nanoparticles, although premature drug release affected formulation performance.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.

Minoxidil effectively treats hair loss, works better for women, and requires consistent use.

This review discusses the potential of nanotechnology-based formulations for delivering topical minoxidil to improve hair loss treatment outcomes and reports no new clinical results, urging further research into their benefits and safety considerations.

This study found that platelet-rich plasma was effective for hair regrowth in women with androgenic alopecia, though less so than minoxidil, but it was associated with improved quality of life responses.

This study found that minoxidil exhibits preferential solvation by water in both water-rich and ethanol-rich solvent mixtures.

This study found that 5% minoxidil topical foam was effective in stabilizing hair density and scalp coverage in men with moderate androgenetic alopecia over 104 weeks, with good safety and tolerability.

This case report describes a 24-year-old woman with androgenetic alopecia who developed sensitivity to topical minoxidil and later to saw palmetto after using a minoxidil and retinoic acid preparation.

This study found that minoxidil stimulates the Kir6.2/SUR2 potassium channel, leading to tumor growth arrest in an ovarian cancer xenograft model by disrupting mitochondrial function and inducing cell death.

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

This case report details two women with female pattern hair loss who experienced severe scalp allergic contact dermatitis from minoxidil, one due to the active ingredient and the other due to the vehicle.

In this study, researchers found that the insignificant cosmetic effect of 5% topical minoxidil solution led to treatment discontinuation among nearly all patients with androgenetic hair loss.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

This abstract discusses platelet-rich plasma therapy for patterned hair loss but provides no new clinical results, suggesting further research is needed to determine its effectiveness.

This study observed that 5% minoxidil topical foam alters gene expression and signaling pathways in the scalp, providing insights into its mechanism of action in men with androgenetic alopecia.

This study found that topical minoxidil 5% gel and spironolactone 1% gel were both effective treatments for androgenetic alopecia, with a combination of both providing the best clinical response and achieving 100% effectiveness among participants.

This study found that combining microneedling with 5% minoxidil improved hair growth in Chinese men with androgenetic alopecia, possibly through activating the Wnt/β-catenin signaling pathway.

Minoxidil reacts to nitrosation 7 times more than phenol, mainly due to its -NH₂ groups, leading to the creation of N-nitrosominoxidil.

This study developed and validated a sensitive method using adsorptive cathodic stripping voltammetry to directly determine minoxidil in topical solutions, shampoos, and creams, achieving high recovery rates and precision.

In this study, intradermal injections of 0.5% minoxidil significantly improved hair growth and volume in women with female androgenetic alopecia compared to a placebo, with a good safety profile reported.

This case report describes a non-arteritic anterior ischemic optic neuropathy that resolved after discontinuing topical 5% minoxidil treatment.

This study developed a micellar electrokinetic capillary chromatography method for determining minoxidil in Rogaine and generic products, offering a simple and efficient alternative to HPLC.

This report documents a case of dermatological toxicity associated with chronic minoxidil therapy, highlighting the emergence of a severe rash after three years of use, which recurred upon inadvertent rechallenge.